Navamedic Asa · OSL:NAVA
Navamedic Asa — Q3 2024 Earnings Presentation
22 slides from Navamedic Asa's earnings presentation, Oct 31, 2024
Slide 1: Q3 and YTD 2024 Highlights and key figures
Q3 and YTD 2024 Highlights and key figures 31 October 2024 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Our edge explained
Our edge explained A reliable supplier of high-quality pharma products, within Prescription drugs (RX), Consumer Health, and Hospital products including Medical nutrition Presence and sales Strong local insight and across the Nordics understanding of patients’ needs Ambitious growth strategy With a
Slide 3: Key financial indicators | Third quarter and nine first months of 2024
Key financial indicators | Third quarter and nine first months of 2024 Business remains strong in a quarter impacted by cyclical nature of the business REVENUE GROSS MARGIN Adjusted EBITDA Double-digit growth in Consumer Health and Q3 123.1 MNOK 37.1% 8.6 MNOK Hospital Nordic tender win in quarter 2
Slide 4: The longer perspective
The longer perspective Growth on a scalable platform and through M&A +5% 500 400 100 Revenue growth and EBITDA NOK million NOK million fluctuations from quarter to 300 quarter mainly due to seasonality and stock build- 200 50 up/down effects 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021
Slide 5: High-quality portfolio with several hero products
High-quality portfolio with several hero products Prescription Drugs (RX) Consumer Health Hospital Sold through pharmacies Sold through pharmacies Antibiotics and Medical nutrition* YTD 2024 YTD 2024 84.3 revenue in revenue in MNOK 195.7 MNOK YTD 2024 97.6 revenue in YoY growth MNOK YoY growth YoY c
Slide 6: Prescription Drugs (RX)
Prescription Drugs (RX) Fluctuations in tenders compared to last year The RX segment comprises Navamedic’s prescription products Q3 2024 revenue 67.1 MNOK MYSIMBA® WHOLESALER VOLUME (Q3 2023: 92.1 MNOK) Vol. (units 000) 200 150 Q3 highlights Strategy for growth Mysimba® showing positive trend • Focu
Slide 7: Consumer Health
Consumer Health Double-digit growth Year-over-Year The Consumer Health segment comprises Navamedic’s over-the-counter products, available to patients without a prescription Q3 2024 revenue 29.3 MNOK (Q3 2023: 25.0 MNOK) Q3 highlights Strategy for growth Modifast delivered strong double-digit growth
Slide 8: Hospital
Hospital Good growth in the quarter and another tender win The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) Q3 2024 revenue 26.6 MNOK (Q3 2023: 24.0 MNOK) Q3 highlights Strategy for growth • Expand
Slide 9: Profitable growth built on our strengths
Antibiotics Hospital segment sales Profitable growth built on our strengths (NOK million) 120 100 Antibiotics + 111% • Antibiotics remain critical to treat 80 from 2021 to LTM Q3'24 bacterial infections 60 • Antimicrobial resistance (AMR) Medical threatens its effectiveness 40 nutrition • Main issue
Slide 10: Delivering on our strategy to become a NOK 1 billion revenue company
Delivering on our strategy to become a NOK 1 billion revenue company with increased profitability GROWTH BASED ON A STRONG FOUNDATION 1 Untapping the potential within existing products, categories and territories. Strengthening the core with a disciplined approach to portfolio management, including
Slide 11: Financials
FINANCIALS @ Navamedic
Slide 12: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures In Q3 2024, revenues were below last year mainly due to the cyclical nature of our business (in NOK '1000) Q3 2024 Q3 2023 YTD 2024 YTD 2023 FY 2023 Gross Profit came in at 37.1% for Q3 Operating revenues 123 062 140 999 400 240 386 686 511 997 mos
Slide 13: Assets
Financials Assets Inventory has decreased in line with (in NOK '1000) 30.09.2024 30.09.2023 31.12.2023 our expectations Goodwill 160 732 140 825 156 729 Trade receivables at normalized level Deferred tax assets 930 835 930 Other intangible assets 93 492 80 821 97 627 Cash level is mostly the combina
Slide 14: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.09.24 30.09.23 31.12.2023 Total equity 264 134 218 269 222 391 Non-current interest-bearing borrowings 87 100 103 292 95 479 Non-current license liabilities 4 166 3 945 3 988 Equity ratio of 50% Non-current right of use liabilities 2 273 4 102 3 89
Slide 15: Cash flow Group – total operations
Financials Cash flow Group – total operations (in NOK '1000) Q3 2024 Q3 2023 YTD 2024 YTD 2023 Year 2023 The cash flow from Operating Activities Net cash flow from operating activities 29 081 25 416 34 622 27 528 2 179 is mainly the result of Net profit Net cash flow from investing activities - 63 -
Slide 16: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 17: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook All business areas and new partnership support continued growth • Navamedic delivered NOK 400.2 million in revenue YTD Q3 2024, representing a Ambition of building a 3.5% increase year-over-year NOK 1 billion • The growth in 2024 is supported by growth in the Hospit
Slide 18: @ Navamedic
@ Navamedic
Slide 19: Want to know more?
Want to know more? Visit our website https://navamedic.com/ Follow us on LinkedIn #InvestInNavamedic Email infono@navamedic.com
Slide 20: Thank you for your attention!
Thank you for your attention! Navamedic’s Q4 2024 presentation will be held on February 12, 2025 20
Slide 21: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 22: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any